Science

Mar 6, 2025, 10:30

Myeloma Paper of the Day, March 6th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Comparison of isatuximab-pom-dex vs. elotuzumab-pom-dex in relapsed/refractory myeloma patients in a target trial emulation using real-world data favors Isa-Pd on some long-term outcomes but shows less infection risk with EloPd.”

“Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data”

Authors: Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Giovanni Tripepi, Massimo Gentile et al.

More posts featuring Robert Orlowski.

Annalisa Pitino cancer Enrica Antonia Martino Giovanni Tripepi Massimo Gentile Massimo Offidani multiple myeloma Myeloma Paper of the Day OncoDaily Oncology relapsed/refractory myeloma Robert Orlowski RRMM

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma